Global Scientific Development in Advanced Cancer Therapies

This section provides educational information on emerging and advanced cancer therapies globally. Please refer to our homepage for services currently offered by SunAct.

Therapies

What is (TIL) Therapy?

TIL therapy is a type of cellular therapy that involves collecting specialized white blood cells called Tumor-Infiltrating Lymphocytes from a tumor, expanding them in a laboratory, and then reinfusing them into the patient’s body to help attack cancer cells.

How does Tumor-Infiltrating Lymphocytes (TIL) Therapy work?

  1. Collection: Tumor-Infiltrating Lymphocytes (TILs) are collected from the patient’s tumor, usually during a biopsy or surgical removal of the tumor.
  2. Activation: In the laboratory, the TILs that naturally recognize and attack the patient’s cancer cells are identified and activated.
  3. Expansion: These activated, cancer-fighting TILs are multiplied into the billions to create a large army, significantly increasing their cancer-fighting power.
  4. Infusion: The expanded army of TILs is infused back into the patient’s bloodstream, similar to a blood transfusion.
  5. Targeting Cancer: Once back in the body, these TILs travel to the tumor sites, seek out the cancer cells they already recognize, and target and destroy them more effectively.

Benefits

Personalized: Uses your own immune cells.

Effective: Especially useful for advanced cancers.

Durable Response: Can lead to long-term remission.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male